Dual site-selective presentation of functional handles on protein-engineered cowpea chlorotic mottle virus-like particles

Citation for published version (APA):
Vervoort, D. F. M., Heiringhoff, R., Timmermans, S. B. P. E., van Stevendaal, M. H. M. E., & van Hest, J. C. M. (2021). Dual site-selective presentation of functional handles on protein-engineered cowpea chlorotic mottle virus-like particles. Bioconjugate Chemistry, 32(5), 958-963. https://doi.org/10.1021/acs.bioconjchem.1c00108

DOI:
10.1021/acs.bioconjchem.1c00108

Document status and date:
Published: 19/05/2021

Document Version:
Publisher’s PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher’s website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.tue.nl/taverne

Take down policy
If you believe that this document breaches copyright please contact us at:
openaccess@tue.nl
providing details and we will investigate your claim.

Download date: 12. Jun. 2022
Dual Site-Selective Presentation of Functional Handles on Protein-Engineered Cowpea Chlorotic Mottle Virus-Like Particles

Daan F. M. Vervoort, Robin Heiringhoff, Suzanne B. P. E. Timmermans, Marleen H. M. E. van Stevendaal, and Jan C. M. van Hest*

Cite This: Bioconjugate Chem. 2021, 32, 958–963

ABSTRACT: Protein cages hold much promise as carrier systems in nanomedicine, due to their well-defined size, cargo-loading capacity, and inherent biodegradability. In order to make them suitable for drug delivery, they have to be stable under physiological conditions. In addition, often surface modifications are required, for example, to improve cell targeting or reduce the particle immunogenicity by PEGylation. For this purpose, we investigated the functionalization capacity of the capsid of cowpea chlorotic mottle virus (CCMV), modified at the interior with a stabilizing elastin-like polypeptide (ELP) tag, by employing a combination of protein engineering and bio-orthogonal chemistry. We first demonstrated the accessibility of the native cysteine residue in ELP-CCMV as a site-selective surface-exposed functional handle, which was not available in the native CCMV capsid. An additional bio-orthogonal functional handle was introduced by incorporation of the noncanonical amino acid, azido-phenylalanine (AzF), using the amber suppression mechanism. Dual site-selective presentation of both a cell-penetrating TAT peptide and a fluorophore to track the particles was demonstrated successfully in HeLa cell uptake studies.

INTRODUCTION

Nanomedicine is a fast-growing field, aiming to improve healthcare in a range of applications, such as medical imaging, vaccines, regenerative medicine, and nanotherapeutics. For this purpose, a large variety of nanoparticles (e.g., liposomes, micelles, metallic, polymeric and protein-based nanoparticles) have been studied. Although the number of clinical trials is rapidly growing and some nanomedicine formulations are already approved for clinical use, there is a constant need to further control particle features in a biological context to ensure a more effective translation to the clinic. In this regard, protein-based virus-like particles (VLPs) are of great interest because of their biocompatibility, well-defined shape and size, the possibilities of cargo encapsulation and ease of modification. One of the most intensely studied VLPs is derived from the cowpea chlorotic mottle virus (CCMV) due to its controllable and reversible self-assembly behavior. This characteristic is of great value, since having good control over assembly and disassembly allows for controlled functionalization of either the interior or exterior. For example, the interior can be functionalized by conjugation of the molecule of interest to the capsid protein N-terminus prior to capsid assembly, whereas surface exposed functional handles at whole capsids can be used for exterior modifications. Since the N-termini of the CCMV capsid proteins (CPs) are predominantly directed toward the inner cavity of the VLP, the N-terminus has extensively been explored for cargo encapsulation. Multiple strategies have been developed, for example via a genetic fusion of the protein of interest with the capsid

Received: March 2, 2021
Revised: March 29, 2021
Published: April 16, 2021

© 2021 The Authors. Published by American Chemical Society

https://doi.org/10.1021/acs.bioconjchem.1c00108
Bioconjugate Chem. 2021, 32, 958–963

958
different surface modifications in a site-selective manner has not yet been studied for CCMV. This is of importance for biomedical applications, as often multiple functionalities are required, for example active targeting of diseased cells using ligands combined with stealth characteristics introduced using poly(ethylene glycol) (PEG).21 Besides surface functionalization capacity, CCMV stability at physiological pH is also a limitation of the native capsid.22 We have recently developed a CCMV variant which showed improved stability under physiological conditions. This was achieved by genetically fusing an elastin-like polypeptide motif (ELPs), consisting of nine repeats of Val-Pro-Gly-Xaa-Gly (VPGXG), to the N-terminus of the CCMV capsid proteins (ELP-CCMV).23 The thermosensitive ELP stabilized capsid protein assembles by increasing the salt concentration or temperature to induce the formation of stable \((T = 1)\) capsids, even in the absence of cargo. In our efforts to modify the ELP-CCMV capsid surface, we observed that, in contrast to the native CCMV, one of the cysteine residues was accessible for chemical modification. Herein, we describe how we have utilized this remarkable feature to develop a CCMV capsid with dual site-selective surface presentation of functional entities by additional incorporation of a noncanonical amino acid using the amber suppression method (Figure 1). For ease of comparison with native CCMV studies, the amino acid positions of both the cysteine and noncanonical amino acid in our ELP-CCMV capsid proteins are based on the wildtype CCMV sequence.

### RESULTS AND DISCUSSION

**Surface Exposed Cysteine Residues in ELP-CCMV Capsids.** Our aim was to develop CCMV capsids that can be used in biomedical applications, for which well-controlled site-selective and multivalent display of functional moieties at the surface is necessary. Exploring the abundantly present, surface-exposed amines (~360 per \(T = 1\) capsid) and carboxylic acids (~660 per \(T = 1\) capsid) does not allow for the required high level of control over the degree of functionalization.17 As the cysteine accessibility was not yet assessed for our newly developed ELP-CCMV capsids, we investigated the classical thiol-maleimide coupling first. In this study, our hydrophobic \((VY1-VY8)\) ELP-CCMV, in which the guest residue X was a tyrosine instead of a valine in the first and eighth repeat of the ELP sequence, was used unless stated otherwise.24,25 We compared the conjugation efficiency of both ELP-CCMV particles and native CCMV particles (heparin stabilized) when incubated with a maleimide-functionalized sulfo-cyanine5 (Cy5; Figure S3). Remarkably, SDS-PAGE analysis demonstrated successful conjugation of Cy5 to ELP-CCMV, while the native CCMV capsid only showed minimal modification (Figure 2A). Image analysis demonstrated a 10-fold increase in conjugation of Cy5 to ELP-CCMV capsids compared to native CCMV capsids.

---

**Figure 1.** Schematic presentation of the exploration of dual site-selective handles on the surface of ELP-CCMV. Native cysteine residues were surface exposed in ELP-CCMV. Via protein engineering a noncanonical amino acid (azido-phenylalanine (K65azF)) was incorporated in ELP-CCMV. Protein engineered K65azF ELP-CCMV capsids therefore displayed both cysteine residues (cyan) and azide functional groups (red) (1 per capsid protein). The functional handles could be independently used for the display of moieties of interest.

**Figure 2.** (A) SDS-PAGE analysis of a maleimide conjugation reaction of sulfo-Cyanine5-maleimide (Cy5) to either ELP-CCMV or native CCMV (heparin stabilized). Coomassie blue staining (left). False color images obtained by illumination (Cy5 excitation at 630 nm) and emission through a 670/10 nm (Cy5) emission filter (right). (B) Analysis of the orientation of cysteines in a native CCMV capsid \((T = 3)\). Space filling model of one trimeric subunit (dark gray) to illustrate the native cysteine at position 59 (yellow) in CCMV capsids (light gray mesh; PDB: 1CWP).26
native CCMV capsids. From literature it is known that the cysteines in native CCMV are not accessible. The reason we observed efficient modification of our CCMV variant can be explained by a conformational change due to the introduction of the ELP-tag, exposing the normally hidden Cys 59 (Figure 2B).

Display of Biomolecules via the Native Cysteine Residue. Next, we investigated the accessibility of the cysteines to more sterically demanding biomolecules, a
negatively charged ssDNA (~6.8 kDa) and a positively charged cell-penetrating peptide, TAT (~1.5 kDa). Both molecules were successfully conjugated to the ELP-CCMV capsids via a maleimide reaction or disulfide bond formation, respectively (Figures S4 and S5). In order to verify that cysteine residue C59 was targeted, the cysteine at position 59 was substituted to a serine (C59S) in our more hydrophobic VW1-VW8 ELP-CCMV (Figure S6). Data indicated that the introduction of this mutation completely prevented labeling with the TAT peptide, demonstrating that C59 was the surface-exposed handle in the ELP-CCMV structure (Figure S7).

**Introduction of a Surface Exposed Noncanonical Amino Acid.** After establishing that ELP-CCMV capsids have one site-selective cysteine handle available, we moved toward introducing a second bio-orthogonal handle on the capsid surface. For this purpose, we investigated the well-established amber suppression method, which allows for the facile, site-selective introduction of a noncanonical amino acid. The amber suppression method has been used previously in MS2 and tobacco mosaic virus (TMV) capsids to add new functional handles but has not been studied for CCMV before. To efficiently use this method to our advantage, amino acid K65, located at a surface-exposed loop (Figure 3A), was predicted to be innocuous with regard to capsid stability and hence could be easily replaced. We thus decided to substitute this lysine for an azido-phenylalanine (K65azF) to provide us with one bio-orthogonal functional handle per capsid protein. Expression and purification were successful, as demonstrated with SDS-PAGE and mass spectrometry (Figure 3B,C). CCMV capsids were next assembled from these K65azF capsid proteins. Two methods were employed; using the traditional pH-induced assembly upon incubation in pH 5 buffer yielded $T = 3$ particles. $T = 1$ particles were formed upon salt-induced, ELP-mediated assembly at pH 7.5. Both assembly states were confirmed with DLS and TEM (Figure 4) and were comparable to ELP-CCMV capsids assembled from the original capsid proteins. By using the incorporated noncanonical amino acid, a fluorophore containing a DBCO group (sulfo-Cyanine5-DBCO) was attached via the copper-free, strain-promoted azide–alkyne cycloaddition (SPAAC) reaction to the azido-handle. SDS-PAGE analysis (Figure 5A) indicated successful and specific labeling of the fluorophore to the K65azF variant, whereas no fluorescence was observed for the CCMV variant without a surface exposed azido-group (K65 ELP-CCMV). Since ELP-CCMV capsids allow for controlled assembly and disassembly, Cy5-labeled capsid proteins were mixed with unlabeled capsid proteins in various ratios, followed by the induction of self-assembly. In order to verify that we mixed capsid proteins instead of capsids, complete disassembly was first confirmed by DLS (Figure S8A). Subsequently, capsid assembly was confirmed with size exclusion chromatography (Figure S8B). SDS-PAGE analysis showed a high level of control over the average incorporation of Cy5-labeled K65azF ELP-CCMV capsid proteins into ELP-CCMV capsids (Figure S9). Furthermore, the thermal stability of the K65azF ELP-CCMV was comparable to the original ELP-CCMV variant and was thus not affected by the incorporation of the noncanonical amino acid (Figure S10). This finding is essential for future applications when these particles with multiple surface-exposed functional handles will be used for nanomedicine purposes. We investigated the possibility of using both surface-exposed handles as a strategy for dual-labeling of the surface. Sulfo-derivatives of Cyanine5-maleimide and DBCO-Cyanine3 were used to ensure solubility in aqueous solutions. SDS-PAGE analysis demonstrated the site-selectivity of this dual-labeling strategy as only K65azF ELP-CCMV was functionalized with both dyes (Figure S5).

**Enhanced Cell-Uptake Using Surface Modified Capsids.** To demonstrate the ability to label the particles with functionally relevant moieties, particles were functionalized with the cell-penetrating peptide (TAT; Figure S11), and a fluorophore using both site-selective handles to allow cell-uptake studies to be performed. To ensure stability of the empty capsids in culture media, a homobifunctional cross-
Applications of multifunctional capsids for future biomedical applications in an orthogonal manner. Remarkably, when using CCMV capsid proteins, which were N-terminally modified with the stabilizing elastin-like polypeptide tag (ELP-CCMV), one of the cysteine residues proved to be sufficiently accessible for modification, in contrast to the native CCMV capsids. A noncanonical amino acid, azido-phenylalanine, was subsequently incorporated as a second handle in a surface-exposed loop using the amber suppression method. Both handles could be addressed effectively and independently of each other, without affecting the capsid stability. Using both handles, capsids displaying both cell-penetrating peptides, TAT, and fluorophores enhanced the uptake in HeLa cells compared to capsids without TAT. This study shows the potential of these multifunctional capsids for future biomedical applications in which often various and multi labeling strategies are necessary at the same time, e.g., targeting moieties, fluorophores, or PEGylation. The use of these site-selective handles enables a much better control over the degree of functionalization compared to traditional nonspecific modifications using amines or carboxylic acids, improving the reproducibility of the particle features, which is an important property for biomedical applications.

ASSOCIATED CONTENT

Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.bioconjchem.1c00108. Experimental methods as well as figures and tables (PDF)

AUTHOR INFORMATION

Corresponding Author
Jan C. M. van Hest — Eindhoven University of Technology, Institute for Complex Molecular Systems, 5600 MB Eindhoven, The Netherlands; orcid.org/0000-0001-7973-2404; Email: J.C.M.v.Hest@tue.nl

Authors
Daan F. M. Vervoort — Eindhoven University of Technology, Institute for Complex Molecular Systems, 5600 MB Eindhoven, The Netherlands

Robin Heirninghoff — Eindhoven University of Technology, Institute for Complex Molecular Systems, 5600 MB Eindhoven, The Netherlands
Suzanne B. P. E. Timmermans — Eindhoven University of Technology, Institute for Complex Molecular Systems, 5600 MB Eindhoven, The Netherlands
Marleen H. M. van Stevendaal — Eindhoven University of Technology, Institute for Complex Molecular Systems, 5600 MB Eindhoven, The Netherlands

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.bioconjchem.1c00108

Funding
This project was financially supported by the ERC Advanced Grant Artisym 694120 and the Dutch Ministry of Education, Culture and Science (Gravitation program 024.001.035).

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENTS
The authors acknowledge Chiara Pretto for providing the heparin induced capsids and Glenn Cremers for providing the ssDNA-maleimide.

ABBREVIATIONS
CCMV, cowpea chlorotic mottle virus; ELP, elastin-like polypeptide; CPP, cell-penetrating peptide; AzF, azido-phenylalanine; TAT, transactivator of transcription; VLPs, virus-like particles; CP, capsid protein; PEG, poly(ethylene glycol); SPAAC, strain-promoted azide–alkyne cycloaddition; BS3, bis(sulfosuccinimidyl)suberate; Cy5, cyanine5

REFERENCES
(1) Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., and Corrie, S. R. (2016) Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm. Res. 33 (10), 2373–2387.
(2) Anselmo, A. C., and Mitragotri, S. (2019) Nanoparticles in the Clinic: An Update. Bioeng. Transl. Med. 4 (3), 1–16.
(3) Koudelka, K. J., Pitek, A. S., Manchester, M., and Steinmetz, N. F. (2015) Virus-Based Nanoparticles as Versatile Nanomachines. Annu. Rev. Virol. 2, 379–401.
(4) Schwarz, B., Uchida, M., and Douglas, T. (2017) Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology. Adv. Virus Res. 97, 1–60.
(5) Chung, Y. H., Cai, H., and Steinmetz, N. F. (2020) Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications. Adv. Drug Delivery Rev. 156, 214–235.
(6) Garcea, R. L., and Gissmann, L. (2004) Virus-like Particles as Vaccines and Vessels for the Delivery of Small Molecules. Curr. Opin. Biotechnol. 15 (6), S13–S17.
(7) Manchester, M., and Steinmetz, N. F. (2009) Viruses and Nanotechnology, Vol. 327; Springer-Verlag: Berlin Heidelberg.
(8) Gillitzer, E., Suci, P., Young, M., and Douglas, T. (2006) Controlled Ligand Display on a Symmetrical Protein-Cage Architecture through Mixed Assembly. Small 2 (8–9), 962–966.
(9) Minten, I. J., Hendriks, L. J. A., Nolte, R. J. M., and Cornelissen, J. J. L. M. (2009) Controlled Encapsulation of Multiple Proteins in Virus Capsids. J. Am. Chem. Soc. 131, 17771–17773.
(10) Wu, Y., Li, J., Yang, H., Seoung, J., Lim, H. D., Kim, G. J., and Shin, H. J. (2017) Targeted Cowpea Chlorotic Mottle Virus-Based Nanoparticles with Tumor-Homing Peptide F3 for Photothermal Therapy. Biotechnol. Bioprocess Eng. 22 (6), 700–708.
(11) Zhao, X., Fox, J. M., Olson, N. H., Baker, T. S., and Young, M. J. (1995) In Vitro Assembly of Cowpea Chlorotic Mottle Virus from
Coat Protein Expressed in Escherichia Coli and in Vitro-Transcribed Viral CDNA. *Virology* 207 (2), 486–494.

(12) Rurup, W. F., Verbij, F., Koay, M. S. T., Blum, C., Subramaniam, V., and Cornelissen, J. J. L. M. (2014) Predicting the Loading of Virus-like Particles with Fluorescent Proteins. *Biomacromolecules* 15 (2), 558–563.

(13) Schoonen, L., Pille, J., Bormann, A., Nolte, R. J. M., and Van Hest, J. C. M. (2015) Sortase A-Mediated N-Terminal Modification of Cowpea Chlorotic Mottle Virus Determined by X-Ray Crystallography and Cryo-Electron Microscopy. *Structure* 3 (30), 4007–4009.

(14) Brash, M., Putri, R. M., de Ruiter, M. V., Luque, D., Koay, M. S. T., Castón, J. R., and Cornelissen, J. J. L. M (2017) Assembling Enzymatic Cascade Pathways inside Virus-Based Nanocages Using Dual-Tasking Nucleic Acid Tags. *J. Am. Chem. Soc.* 139, 1512–1519.

(15) Minten, I. J., Claessen, V. I., Blank, K., Rowan, A. E., Nolte, R. J. M., and Cornelissen, J. J. L. M (2011) Catalytic Capsids: The Art of Confinement. *Chem. Sci.* 2 (2), 358–362.

(16) Schoonen, L., Eising, S., Van Eldijk, M. B., Bresseleers, J., Van Der Pijl, M., Nolte, R. J. M., Bonger, K. M., and Van Hest, J. C. M. (2018) Modular, Bioorthogonal Strategy for the Controlled Loading of Cargo into a Protein Nanocage. *Bioconjugate Chem.* 29 (4), 1186–1193.

(17) Gillitzer, E., Willits, D., Young, M., and Douglas, T. (2002) Chemical Modification of a Viral Cage for Multivalent Presentation. *Chem. Commun.*, 2390–2391.

(18) Comellas-Aragonès, M., de la Escosura, A., Dirks, A. J., van der Ham, A., Fusté-Cuñe, A., Cornelissen, J. J. L. M., and Nolte, R. J. M. (2009) Controlled Integration of Polymers into Viral Capsids. *Biomacromolecules* 10, 3141–3147.

(19) Krall, N., Da Cruz, F. P., Boutureira, O., and Bernardes, G. J. L. (2016) Site-Selective Protein-Modification Chemistry for Basic Biology and Drug Development. *Nat. Chem.* 8 (2), 103–113.

(20) Kaiser, C. R., Flenniken, M. L., Gillitzer, E., Harmsen, A. G. A. L., Harmsen, A. G. A. L., Jutila, M. A., Douglas, T., and Young, M. J. (2007) Biodistribution Studies of Protein Cage Nanoparticles Demonstrate Broad Tissue Distribution and Rapid Clearance in Vivo. *Int. J. Nanomedicine* 2 (4), 715–733.

(21) van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., and van Gaal, E. V. B. (2013) Ligand-Targeted Particulate Nanomedicines Undergoing Clinical Evaluation: Current Status. *Adv. Drug Delivery Rev.* 65 (10), 1284–1298.

(22) Lavelle, L., Michel, J. P., and Gingery, M. (2007) The Disassembly, Reassembly and Stability of CCMV Capsid Proteins. *J. Virol. Methods* 146 (1–2), 311–316.

(23) van Eldijk, M. B., Wang, J. C.-Y., Minten, I. J., Li, C., Zlotnick, A., Nolte, R. J. M., Cornelissen, J. J. L. M., and van Hest, J. C. M. (2012) Designing Two Self-Assembly Mechanisms into One Viral Capsid Protein. *J. Am. Chem. Soc.* 134, 18506–18509.

(24) Schoonen, L., Maas, R. J. M., Nolte, R. J. M., and van Hest, J. C. M. (2017) Expansion of the Assembly of Cowpea Chlorotic Mottle Virus towards Non-Native and Physiological Conditions. *Tetrahedron* 73 (33), 4968–4971.

(25) Timmermans, S. B. P. E., Vervoort, D. F. M., Schoonen, L., Nolte, R. J. M., and van Hest, J. C. M. (2018) Self-Assembly and Stabilization of Hybrid Cowpea Chlorotic Mottle Virus Particles under Nearly Physiological Conditions. *Chem. - Asian J.* 13 (22), 3518–3525.

(26) Speir, J. A., Munshi, S., Wang, G., Baker, T. S., and Johnson, J. E. (1995) Structures of the Native and Swollen Forms of Cowpea Chlorotic Mottle Virus Determined by X-Ray Crystallography and Cryo-Electron Microscopy. *Structure* 3 (1), 63–78.

(27) Tong, G. J., Hisiao, S. C., Carrico, Z. M., and Francis, M. B. (2009) Viral Capsid DNA Aptamer Conjugates as Multivalent Cell-Targeting Vehicules. *J. Am. Chem. Soc.* 131 (31), 11174–11178.

(28) Wu, F. C., Zhang, H., Zhou, Q., Wu, M., Ballard, Z., Tian, Y., Wang, J. Y., Niu, Z. W., and Huang, Y. (2014) Expanding the Genetic Code for Site-Specific Labelling of Tobacco Mosaic Virus Coat Protein and Building Biotin-Functionalized Virus-like Particles. *Chem. Commun.* 50 (30), 4007–4009.

(29) Pretto, C., and Van Hest, J. C. M. (2019) Versatile Reversible Cross-Linking Strategy to Stabilize CCMV Virus like Particles for Efficient siRNA Delivery. *Bioconjugate Chem.* 30 (12), 3069–3077.

(30) Villagran-Escareño, M. V., Reynaga-Hernández, E., Galicia-Cruz, O. G., Durán-Meza, A. L., De La Cruz-González, V., Hernández-Carballo, C. Y., and Ruiz-García, J. (2019) VLPs Derived from the CCMV Plant Virus Can Directly Transfect and Deliver Heterologous Genes for Translation into Mammalian Cells. *BioMed Res. Int.* 2019, 1.